Global Hormonal Therapy Market
Global Hormonal Therapy Market

Hormonal Therapy Comprehensive Study by Therapy (Estrogen Hormone Therapy, Human Growth Hormone Therapy, Thyroid Hormone Therapy, Testosterone Hormone Therapy, Progestogen Hormone Therapy, Others), Administration (Oral, Parenteral), Indication (Menopause, Male Hypogonadism, Hypothyroidism, Growth Hormone Deficiency, Others), End Use (Hospitals, Specialty Clinics) Players and Region - Global Market Outlook to 2026

Hormonal Therapy Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Aug 2021 Edition 225 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Hormonal Therapy Market Scope
Hormone therapy is defined a systemic treatment since the hormones it targets circulate throughout the body. Hormone therapy medications go throughout the body in order to target and locate the hormones. This distinguishes it from treatments that exclusively target a specific portion of the body, such as most types of surgery and radiation therapy. These kinds of therapies are known as local treatments since they only affect one portion of the body. Hormonal therapy is also known as hormone withdrawal therapy, endocrine therapy, and hormone manipulation therapy. Majority of the hormones used in this treatment are female hormones. Hormone therapy is a common treatment for menopausal symptoms. Cancers such as prostate and breast cancer are also treated with hormone treatment.

The Hormonal Therapy market study is segmented and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Hormonal Therapy market throughout the predicted period.

Abbott Laboratories (United States), Bayer AG (Germany), Eli Lilly and Company (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Merck KGaA (Germany), Mylan N.V. (United States), Novartis International AG (Switzerland), Novo Nordisk A/S (Denmark) and Pfizer Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Amgen (United States), Myovant Sciences GmbH. (Germany), Genentech, Inc. (United States), Allergan plc (Ireland) and Teva Pharmaceutical Industries Ltd (Israel).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Hormonal Therapy market by Type, Application and Region.

On the basis of geography, the market of Hormonal Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies

On 18th December, 2020 - Myovant Sciences Received FDA Approval for First Oral Hormone Therapy for Treating Advanced Prostate Cancer. Orgovyx is An Orally Administered Medication That Functions by Preventing the Pituitary Gland from Producing Luteinizing Hormone and Follicle-Stimulating Hormone.


Market Trend
  • Emergence of Advance Novel Delivery Systems in Drug Development

Market Drivers
  • Prevalence of Breast Cancer and Hormonal Disorders
  • Rising Awareness on Post-menopausal Issues Among Females

Opportunities
  • Growth in Healthcare Infrastructure Across Emerging Regions

Restraints
  • Substantial Risk of Cancer Associated to Hormone Therapy
  • High-Cost of Treatment

Challenges
  • Lack of Trained Professionals
  • Regulatory Approval


Key Target Audience
Hormonal Therapy Solution Providers, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Hormonal Therapy Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Therapy
  • Estrogen Hormone Therapy
  • Human Growth Hormone Therapy
  • Thyroid Hormone Therapy
  • Testosterone Hormone Therapy
  • Progestogen Hormone Therapy
  • Others

By Administration
  • Oral
  • Parenteral

By Indication
  • Menopause
  • Male Hypogonadism
  • Hypothyroidism
  • Growth Hormone Deficiency
  • Others

By End Use
  • Hospitals
  • Specialty Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Breast Cancer and Hormonal Disorders
      • 3.2.2. Rising Awareness on Post-menopausal Issues Among Females
    • 3.3. Market Challenges
      • 3.3.1. Lack of Trained Professionals
      • 3.3.2. Regulatory Approval
    • 3.4. Market Trends
      • 3.4.1. Emergence of Advance Novel Delivery Systems in Drug Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hormonal Therapy, by Therapy, Administration, Indication, End Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Hormonal Therapy (Value)
      • 5.2.1. Global Hormonal Therapy by: Therapy (Value)
        • 5.2.1.1. Estrogen Hormone Therapy
        • 5.2.1.2. Human Growth Hormone Therapy
        • 5.2.1.3. Thyroid Hormone Therapy
        • 5.2.1.4. Testosterone Hormone Therapy
        • 5.2.1.5. Progestogen Hormone Therapy
        • 5.2.1.6. Others
      • 5.2.2. Global Hormonal Therapy by: Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parenteral
      • 5.2.3. Global Hormonal Therapy by: Indication (Value)
        • 5.2.3.1. Menopause
        • 5.2.3.2. Male Hypogonadism
        • 5.2.3.3. Hypothyroidism
        • 5.2.3.4. Growth Hormone Deficiency
        • 5.2.3.5. Others
      • 5.2.4. Global Hormonal Therapy by: End Use (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Specialty Clinics
      • 5.2.5. Global Hormonal Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Hormonal Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Hisamitsu Pharmaceutical Co., Inc. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck KGaA (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Mylan N.V. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis International AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novo Nordisk A/S (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hormonal Therapy Sale, by Therapy, Administration, Indication, End Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Hormonal Therapy (Value)
      • 7.2.1. Global Hormonal Therapy by: Therapy (Value)
        • 7.2.1.1. Estrogen Hormone Therapy
        • 7.2.1.2. Human Growth Hormone Therapy
        • 7.2.1.3. Thyroid Hormone Therapy
        • 7.2.1.4. Testosterone Hormone Therapy
        • 7.2.1.5. Progestogen Hormone Therapy
        • 7.2.1.6. Others
      • 7.2.2. Global Hormonal Therapy by: Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parenteral
      • 7.2.3. Global Hormonal Therapy by: Indication (Value)
        • 7.2.3.1. Menopause
        • 7.2.3.2. Male Hypogonadism
        • 7.2.3.3. Hypothyroidism
        • 7.2.3.4. Growth Hormone Deficiency
        • 7.2.3.5. Others
      • 7.2.4. Global Hormonal Therapy by: End Use (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Specialty Clinics
      • 7.2.5. Global Hormonal Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hormonal Therapy: by Therapy(USD Million)
  • Table 2. Hormonal Therapy Estrogen Hormone Therapy , by Region USD Million (2015-2020)
  • Table 3. Hormonal Therapy Human Growth Hormone Therapy , by Region USD Million (2015-2020)
  • Table 4. Hormonal Therapy Thyroid Hormone Therapy , by Region USD Million (2015-2020)
  • Table 5. Hormonal Therapy Testosterone Hormone Therapy , by Region USD Million (2015-2020)
  • Table 6. Hormonal Therapy Progestogen Hormone Therapy , by Region USD Million (2015-2020)
  • Table 7. Hormonal Therapy Others , by Region USD Million (2015-2020)
  • Table 8. Hormonal Therapy: by Administration(USD Million)
  • Table 9. Hormonal Therapy Oral , by Region USD Million (2015-2020)
  • Table 10. Hormonal Therapy Parenteral , by Region USD Million (2015-2020)
  • Table 11. Hormonal Therapy: by Indication(USD Million)
  • Table 12. Hormonal Therapy Menopause , by Region USD Million (2015-2020)
  • Table 13. Hormonal Therapy Male Hypogonadism , by Region USD Million (2015-2020)
  • Table 14. Hormonal Therapy Hypothyroidism , by Region USD Million (2015-2020)
  • Table 15. Hormonal Therapy Growth Hormone Deficiency , by Region USD Million (2015-2020)
  • Table 16. Hormonal Therapy Others , by Region USD Million (2015-2020)
  • Table 17. Hormonal Therapy: by End Use(USD Million)
  • Table 18. Hormonal Therapy Hospitals , by Region USD Million (2015-2020)
  • Table 19. Hormonal Therapy Specialty Clinics , by Region USD Million (2015-2020)
  • Table 20. South America Hormonal Therapy, by Country USD Million (2015-2020)
  • Table 21. South America Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 22. South America Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 23. South America Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 24. South America Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 25. Brazil Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 26. Brazil Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 27. Brazil Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 28. Brazil Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 29. Argentina Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 30. Argentina Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 31. Argentina Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 32. Argentina Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 33. Rest of South America Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 34. Rest of South America Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 35. Rest of South America Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 36. Rest of South America Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 37. Asia Pacific Hormonal Therapy, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 39. Asia Pacific Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 40. Asia Pacific Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 41. Asia Pacific Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 42. China Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 43. China Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 44. China Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 45. China Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 46. Japan Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 47. Japan Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 48. Japan Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 49. Japan Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 50. India Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 51. India Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 52. India Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 53. India Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 54. South Korea Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 55. South Korea Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 56. South Korea Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 57. South Korea Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 58. Taiwan Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 59. Taiwan Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 60. Taiwan Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 61. Taiwan Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 62. Australia Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 63. Australia Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 64. Australia Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 65. Australia Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 70. Europe Hormonal Therapy, by Country USD Million (2015-2020)
  • Table 71. Europe Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 72. Europe Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 73. Europe Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 74. Europe Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 75. Germany Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 76. Germany Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 77. Germany Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 78. Germany Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 79. France Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 80. France Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 81. France Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 82. France Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 83. Italy Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 84. Italy Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 85. Italy Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 86. Italy Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 87. United Kingdom Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 88. United Kingdom Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 89. United Kingdom Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 90. United Kingdom Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 91. Netherlands Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 92. Netherlands Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 93. Netherlands Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 94. Netherlands Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 95. Rest of Europe Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 96. Rest of Europe Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 97. Rest of Europe Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 98. Rest of Europe Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 99. MEA Hormonal Therapy, by Country USD Million (2015-2020)
  • Table 100. MEA Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 101. MEA Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 102. MEA Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 103. MEA Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 104. Middle East Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 105. Middle East Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 106. Middle East Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 107. Middle East Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 108. Africa Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 109. Africa Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 110. Africa Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 111. Africa Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 112. North America Hormonal Therapy, by Country USD Million (2015-2020)
  • Table 113. North America Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 114. North America Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 115. North America Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 116. North America Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 117. United States Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 118. United States Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 119. United States Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 120. United States Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 121. Canada Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 122. Canada Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 123. Canada Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 124. Canada Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 125. Mexico Hormonal Therapy, by Therapy USD Million (2015-2020)
  • Table 126. Mexico Hormonal Therapy, by Administration USD Million (2015-2020)
  • Table 127. Mexico Hormonal Therapy, by Indication USD Million (2015-2020)
  • Table 128. Mexico Hormonal Therapy, by End Use USD Million (2015-2020)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Hormonal Therapy: by Therapy(USD Million)
  • Table 140. Hormonal Therapy Estrogen Hormone Therapy , by Region USD Million (2021-2026)
  • Table 141. Hormonal Therapy Human Growth Hormone Therapy , by Region USD Million (2021-2026)
  • Table 142. Hormonal Therapy Thyroid Hormone Therapy , by Region USD Million (2021-2026)
  • Table 143. Hormonal Therapy Testosterone Hormone Therapy , by Region USD Million (2021-2026)
  • Table 144. Hormonal Therapy Progestogen Hormone Therapy , by Region USD Million (2021-2026)
  • Table 145. Hormonal Therapy Others , by Region USD Million (2021-2026)
  • Table 146. Hormonal Therapy: by Administration(USD Million)
  • Table 147. Hormonal Therapy Oral , by Region USD Million (2021-2026)
  • Table 148. Hormonal Therapy Parenteral , by Region USD Million (2021-2026)
  • Table 149. Hormonal Therapy: by Indication(USD Million)
  • Table 150. Hormonal Therapy Menopause , by Region USD Million (2021-2026)
  • Table 151. Hormonal Therapy Male Hypogonadism , by Region USD Million (2021-2026)
  • Table 152. Hormonal Therapy Hypothyroidism , by Region USD Million (2021-2026)
  • Table 153. Hormonal Therapy Growth Hormone Deficiency , by Region USD Million (2021-2026)
  • Table 154. Hormonal Therapy Others , by Region USD Million (2021-2026)
  • Table 155. Hormonal Therapy: by End Use(USD Million)
  • Table 156. Hormonal Therapy Hospitals , by Region USD Million (2021-2026)
  • Table 157. Hormonal Therapy Specialty Clinics , by Region USD Million (2021-2026)
  • Table 158. South America Hormonal Therapy, by Country USD Million (2021-2026)
  • Table 159. South America Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 160. South America Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 161. South America Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 162. South America Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 163. Brazil Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 164. Brazil Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 165. Brazil Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 166. Brazil Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 167. Argentina Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 168. Argentina Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 169. Argentina Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 170. Argentina Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 171. Rest of South America Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 172. Rest of South America Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 173. Rest of South America Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 174. Rest of South America Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 175. Asia Pacific Hormonal Therapy, by Country USD Million (2021-2026)
  • Table 176. Asia Pacific Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 177. Asia Pacific Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 178. Asia Pacific Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 179. Asia Pacific Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 180. China Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 181. China Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 182. China Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 183. China Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 184. Japan Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 185. Japan Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 186. Japan Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 187. Japan Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 188. India Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 189. India Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 190. India Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 191. India Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 192. South Korea Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 193. South Korea Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 194. South Korea Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 195. South Korea Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 196. Taiwan Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 197. Taiwan Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 198. Taiwan Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 199. Taiwan Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 200. Australia Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 201. Australia Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 202. Australia Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 203. Australia Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 208. Europe Hormonal Therapy, by Country USD Million (2021-2026)
  • Table 209. Europe Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 210. Europe Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 211. Europe Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 212. Europe Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 213. Germany Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 214. Germany Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 215. Germany Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 216. Germany Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 217. France Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 218. France Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 219. France Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 220. France Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 221. Italy Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 222. Italy Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 223. Italy Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 224. Italy Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 225. United Kingdom Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 226. United Kingdom Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 227. United Kingdom Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 228. United Kingdom Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 229. Netherlands Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 230. Netherlands Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 231. Netherlands Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 232. Netherlands Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 233. Rest of Europe Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 234. Rest of Europe Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 235. Rest of Europe Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 236. Rest of Europe Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 237. MEA Hormonal Therapy, by Country USD Million (2021-2026)
  • Table 238. MEA Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 239. MEA Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 240. MEA Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 241. MEA Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 242. Middle East Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 243. Middle East Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 244. Middle East Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 245. Middle East Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 246. Africa Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 247. Africa Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 248. Africa Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 249. Africa Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 250. North America Hormonal Therapy, by Country USD Million (2021-2026)
  • Table 251. North America Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 252. North America Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 253. North America Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 254. North America Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 255. United States Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 256. United States Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 257. United States Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 258. United States Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 259. Canada Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 260. Canada Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 261. Canada Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 262. Canada Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 263. Mexico Hormonal Therapy, by Therapy USD Million (2021-2026)
  • Table 264. Mexico Hormonal Therapy, by Administration USD Million (2021-2026)
  • Table 265. Mexico Hormonal Therapy, by Indication USD Million (2021-2026)
  • Table 266. Mexico Hormonal Therapy, by End Use USD Million (2021-2026)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hormonal Therapy: by Therapy USD Million (2015-2020)
  • Figure 5. Global Hormonal Therapy: by Administration USD Million (2015-2020)
  • Figure 6. Global Hormonal Therapy: by Indication USD Million (2015-2020)
  • Figure 7. Global Hormonal Therapy: by End Use USD Million (2015-2020)
  • Figure 8. South America Hormonal Therapy Share (%), by Country
  • Figure 9. Asia Pacific Hormonal Therapy Share (%), by Country
  • Figure 10. Europe Hormonal Therapy Share (%), by Country
  • Figure 11. MEA Hormonal Therapy Share (%), by Country
  • Figure 12. North America Hormonal Therapy Share (%), by Country
  • Figure 13. Global Hormonal Therapy share by Players 2020 (%)
  • Figure 14. Global Hormonal Therapy share by Players (Top 3) 2020(%)
  • Figure 15. Global Hormonal Therapy share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 19. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 20. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 21. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 22. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 23. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 25. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue: by Geography 2020
  • Figure 27. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 29. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Mylan N.V. (United States) Revenue: by Geography 2020
  • Figure 31. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 33. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 34. Novo Nordisk A/S (Denmark) Revenue: by Geography 2020
  • Figure 35. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 37. Global Hormonal Therapy: by Therapy USD Million (2021-2026)
  • Figure 38. Global Hormonal Therapy: by Administration USD Million (2021-2026)
  • Figure 39. Global Hormonal Therapy: by Indication USD Million (2021-2026)
  • Figure 40. Global Hormonal Therapy: by End Use USD Million (2021-2026)
  • Figure 41. South America Hormonal Therapy Share (%), by Country
  • Figure 42. Asia Pacific Hormonal Therapy Share (%), by Country
  • Figure 43. Europe Hormonal Therapy Share (%), by Country
  • Figure 44. MEA Hormonal Therapy Share (%), by Country
  • Figure 45. North America Hormonal Therapy Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Abbott Laboratories (United States)
  • Bayer AG (Germany)
  • Eli Lilly and Company (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • Merck KGaA (Germany)
  • Mylan N.V. (United States)
  • Novartis International AG (Switzerland)
  • Novo Nordisk A/S (Denmark)
  • Pfizer Inc. (United States)
Additional players considered in the study are as follows:
Amgen (United States) , Myovant Sciences GmbH. (Germany) , Genentech, Inc. (United States) , Allergan plc (Ireland) , Teva Pharmaceutical Industries Ltd (Israel)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation